It May Be Possible To Delay The Onset Of Neurodegenerative Diseases With An Immunosuppressive Drug
The collaboration of the research group led by Dr. Ferrer with SISSA researchers began five years ago when they observed that Parkinson's patients showed a deficit in UCHL1 protein. At that time, researchers didn't know what mechanism produced this deficit. To discover it a European project was launched. It was coordinated by the Italian researchers and participated by other European research groups, including the group led by Dr. Ferrer. The project, called Dopaminet, focused on how dopaminergic neurons (brain cells whose neurotransmitter is dopamine) are involved in Parkinson's disease.
Contrary to most common hypothesis that a DNA fragment encodes a protein through a messenger RNA molecule, the researchers found that it also works in reverse. They found a balance between the protein and its mirror protein, which is configured in reverse, and they are mutually controlled. If the protein mirror is located in the nucleus of the cell, it does not interact with the protein, while if it is in the cytoplasm, then both of them interact.
In the case of Parkinson's disease the protein UCHL1 appears reduced and also its mirror protein is localized in the nucleus, and in the cytoplasm. Thus, the researchers sought a method to extract the mirror protein from the nucleus and made it interact with the original UCHL1 protein. The authors found that rapamycin was able to extract them from the nucleus. The drug allows the two proteins, the UCHL1 and its mirror, hold together in the cytoplasm, which would correct the mistakes that occur in Parkinson's disease.
This in vitro research has allowed describing a new unknown mechanism. It is necessary that the UCHL1 mirror protein should accumulate in the nucleus and escape from the cytoplasm and join the UCLH1 protein. The combination of both makes the system work.
"The rapamycin can not cure Parkinson's disease, but it may delay the onset of neurodegenerative diseases such as Alzheimer's and Parkinson's itself. Rapamycin can protect and delay the beginning of these diseases. It can complete the treatment, but it should be combined with other existing treatments", explains Isidro Ferrer.
Anyway, it is still far its application in patients. The next step is to validate these results in animal models and study the effects of rapamycin in combination with other drugs.
Please use one of the following formats to cite this article in your essay, paper or report:
IDIBELL-Bellvitge Biomedical Research Institute. "It May Be Possible To Delay The Onset Of Neurodegenerative Diseases With An Immunosuppressive Drug." Medical News Today. MediLexicon, Intl., 16 Oct. 2012. Web.
7 Feb. 2016. <http://www.medicalnewstoday.com/releases/251525.php>
IDIBELL-Bellvitge Biomedical Research Institute. (2012, October 16). "It May Be Possible To Delay The Onset Of Neurodegenerative Diseases With An Immunosuppressive Drug." Medical News Today. Retrieved from
Please note: If no author information is provided, the source is cited instead.
Contact our news editors
For any corrections of factual information, or to contact our editorial team, please see our contact page.
Copyright Medical News Today: Excluding email/sharing services explicitly offered on this website, material published on Medical News Today may not be reproduced, or distributed without the prior written permission of Medilexicon International Ltd. Please contact us for further details.